FCS Disease Site Committee Formed
FORT
MYERS, Fla., May 21, 2024
/PRNewswire/ -- Florida Cancer Specialists & Research
Institute, LLC (FCS) is proud to announce an initiative aimed at
revolutionizing cancer care – the introduction of designated FCS
Disease Site Teams for late-phase research and the subsequent
formation of the FCS Disease Site Committee. With an unwavering
commitment to excellence in cancer research and treatment, FCS is
setting a new standard in personalized care by dedicating
specialized teams to focus on specific cancer types in late-phase
studies.
Led by FCS world-renowned medical oncologists and hematologists
and supported by a multidisciplinary team of experts, each Disease
Site Team is set to address the unique challenges and intricacies
associated with different types of cancer, specifically in
late-phase research. These efforts will complement the early-phase
research completed at each of FCS' Drug Development Units (DDUs)
with oversight by FCS Director of Drug Development Manish R. Patel, MD. By concentrating their
expertise and resources, these site-specific teams are poised to
drive groundbreaking advancements in the understanding, diagnosis,
and treatment of cancer in its advanced stages.
"We believe that by channeling our collective knowledge and
resources into specialized teams for late-phase research, we can
accelerate progress in bringing promising therapies to patients who
urgently need them," said Lucio N.
Gordan, MD, president & managing physician at FCS. "The
Disease Site Committee embodies our commitment to providing
unparalleled care and pushing the boundaries of oncology
research."
The Disease Site Teams will focus on a range of cancer types,
including but not limited to breast cancer, gynecologic,
gastrointestinal, skin and thoracic cancers in late-phase studies.
Each team will leverage superior technologies, collaborate closely
with FCS' research partner Sarah Cannon Research Institute and
participate in clinical trials to pioneer innovative approaches in
cancer care for patients at advanced stages of the disease.
Members of the FCS Disease Site Committee include:
Breast
- Shaachi Gupta, MD
- Muhammad Imam, MD
Gastrointestinal (GI)
- Syed Zafar, MD
- Anjan J. Patel, MD
Genitourinary (GU)
- William Grow, MD
- Judah Friedman, MD
Gynecologic (GYN) and Other
- Bradley Monk, MD
- Elizabeth Guancial, MD
Head and Neck
- Amir Harandi, MD, MS
- Cesar Augusto Perez, MD
Hematology
- Shachar Peles, MD
- Gustavo Fonseca, MD
- Blessy Jacob, MD
Skin
Thoracic
- Maen Hussein, MD
- Ernesto Bustinza-Linares,
MD
- Fadi Kayali, MD
"Our goal is to improve outcomes for patients facing advanced
cancer and contribute to the global fight against cancer in its
many forms," added FCS Medical Director of Late-Phase Research
Bradley J. Monk, MD. "Through these
specialized teams, we aim to uncover new insights, develop novel
therapies, and ultimately transform the landscape of oncology."
As part of its commitment to transparency and patient-centered
care, FCS will regularly communicate updates and findings from the
Disease Site Committee. Through shared knowledge and collaboration,
the statewide practice is upholding its mission of providing
patient-centered care and inspiring hope powered by science and
innovation.
For more information about the FCS Disease Site Committee,
please visit: https://flcancer.com/clinical-trials-team/.
About Florida Cancer Specialists & Research Institute,
LLC: (FLCancer.com)
Florida Cancer Specialists &
Research Institute (FCS) offers patients access to more clinical
trials than any private oncology practice in Florida. The majority of new cancer drugs
recently approved for use in the U.S. were studied in clinical
trials with FCS participation.* Recognized for our research, FCS is
a recipient of the national Clinical Trials Participation Award
presented by the American Society of Clinical Oncology (ASCO). FCS
physicians, trained in prestigious medical schools and research
institutes, are consistently ranked nationally as Top Doctors by
U.S. News & World Report.
Celebrating its 40th year in 2024, FCS has built a
national reputation for excellence that is reflected in exceptional
and compassionate patient care, driven by innovative clinical
research, cutting-edge technologies and advanced treatments,
including targeted therapies genomic-based treatment and
immunotherapy. Our highest values are embodied by our outstanding
team of highly trained and dedicated physicians, clinicians and
staff.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/unveiling-the-future-of-oncology-specialized-teams-at-florida-cancer-specialists--research-institute-target-advanced-cancer-treatments-302151607.html
SOURCE Florida Cancer Specialists & Research Institute